Eosinophilic gastritis is a rare inflammatory condition that requires careful management through dietary adjustments, medications, or a combination of both to control symptoms and reduce stomach inflammation.

How Treatment Helps People Living with Eosinophilic Gastritis

When someone receives a diagnosis of eosinophilic gastritis, the main focus of treatment is to reduce the number of eosinophils—a type of white blood cell—that have accumulated in the stomach lining. These cells normally protect the body from infections and parasites, but when they build up in excessive numbers, they release substances that damage and inflame the stomach tissue. Treatment aims to bring symptoms like nausea, abdominal pain, and vomiting under control, allowing people to eat more comfortably and maintain proper nutrition. The ultimate goals include improving quality of life, preventing complications such as anemia from ongoing inflammation, and helping children grow at a healthy rate.^[1][2]

The approach to treating eosinophilic gastritis depends on several factors, including the severity of symptoms, the patient’s age, and whether other parts of the digestive system are affected. Some patients respond well to changes in diet alone, while others need medications to suppress the immune response driving the inflammation. Because this condition is chronic—meaning it persists over time—many people require ongoing therapy to keep symptoms from returning. Healthcare providers tailor treatment plans to each individual, taking into account personal preferences, lifestyle, and how well someone tolerates different interventions.^[4][6]

An important aspect of treatment planning involves understanding that there is currently no universally accepted guideline for eosinophilic gastritis. Unlike its more common cousin, eosinophilic esophagitis, which affects the esophagus, eosinophilic gastritis has been less extensively studied due to its rarity. This makes diagnosis and treatment more challenging, as doctors often rely on their clinical experience and knowledge from related conditions. However, ongoing research through clinical trials is working to identify better treatment options and establish clearer standards of care for patients living with this condition.^[2][13]

Standard Treatment Approaches

The cornerstone of managing eosinophilic gastritis involves two main strategies: dietary modifications and medication therapy. These approaches can be used individually or together, depending on how someone responds to treatment. The decision about which path to follow is typically made through shared decision-making between the patient, their family members or caregivers, and their medical team.^[4][11]

Dietary Therapy

Food allergies or sensitivities are believed to play a role in triggering the abnormal immune response that causes eosinophils to accumulate in the stomach. For this reason, dietary changes represent one of the first-line treatment options for eosinophilic gastritis. There are several different dietary approaches that doctors may recommend, each with its own advantages and challenges.^[4][11]

The most restrictive option is an elemental diet, in which a person consumes only a specialized formula made of amino acids—the building blocks of proteins. This formula contains no intact proteins that could trigger an allergic response. While elemental diets have shown strong results in reducing eosinophil counts, they can be extremely difficult to follow because they require giving up all regular food. This approach can significantly affect quality of life and is particularly challenging for children and adults who enjoy eating solid meals. For this reason, elemental diets are often reserved for cases where other treatments have failed.^[11]

A more practical approach is the empiric elimination diet, which removes the most common food allergens from the diet regardless of whether allergy testing showed positive results. The traditional version eliminates six foods: milk, eggs, wheat, soy, nuts, and fish or seafood. This is known as the six-food elimination diet. Recent research has shown that eliminating just one food—animal milk—can be as effective as removing all six foods in many adults with eosinophilic esophagitis, a finding that may also apply to eosinophilic gastritis. After a period of avoidance, foods are gradually reintroduced one at a time to identify which specific foods trigger symptoms. This process requires patience and careful monitoring through repeated endoscopy procedures to check eosinophil levels.^[11][19]

The third dietary option is allergy testing-directed food elimination, which involves avoiding only those foods that tested positive on skin-prick tests or blood tests for specific antibodies. However, this approach has limitations because standard allergy tests do not always identify the foods causing problems in eosinophilic gastritis. The immune reaction in this condition can involve pathways that these tests do not measure.^[11]

In infants with eosinophilic gastritis, changing to a different formula may be sufficient to control symptoms. This might mean switching to a hypoallergenic formula or one based on amino acids rather than cow’s milk protein.^[2]

Medication Therapy

Corticosteroids—medications that reduce inflammation by suppressing the immune system—remain the primary drug treatment for eosinophilic gastritis. These medications work by decreasing the activity of immune cells, including eosinophils, and reducing the release of inflammatory substances in the stomach lining. Corticosteroids can be highly effective at bringing symptoms under control and lowering eosinophil counts in tissue biopsies.^[5][9]

The most commonly used corticosteroid for eosinophilic gastritis is prednisone, which is taken by mouth as a pill or liquid. Treatment typically begins with a higher dose to induce remission—meaning to get the disease under control—followed by a gradual reduction in dose over several weeks or months. The length of treatment varies depending on how well someone responds, but it often lasts for several weeks during the initial phase.^[9]

Another corticosteroid option is budesonide, which is designed to work primarily in the gastrointestinal tract with less absorption into the bloodstream. This means it may cause fewer side effects throughout the body compared to prednisone. Budesonide comes in different formulations, and some are specifically designed to release the medication in certain parts of the digestive system.^[9]

While corticosteroids can be very effective, they come with potential side effects, especially when used for long periods. Short-term use may cause increased appetite, mood changes, difficulty sleeping, and temporary increases in blood sugar. Prolonged use can lead to more serious problems such as weight gain, weakened bones (osteoporosis), increased risk of infections, elevated blood pressure, cataracts, and suppression of the body’s natural cortisol production. For this reason, doctors try to use the lowest effective dose for the shortest time necessary, and they may look for alternative treatments for people who need long-term therapy.^[9]

Other medications have been tried in small numbers of patients with eosinophilic gastritis, though evidence for their effectiveness is more limited. Mast cell stabilizers, such as cromolyn sodium, work by preventing certain immune cells from releasing inflammatory substances. Leukotriene inhibitors, such as montelukast, block the action of chemicals involved in allergic reactions. Antihistamines reduce the effects of histamine, another chemical released during allergic responses. Immunosuppressive medications like azathioprine have been used in some cases to suppress the overall immune response. These alternatives are sometimes considered for patients who cannot tolerate corticosteroids or who need long-term treatment, but more research is needed to establish their role in therapy.^[9]

For patients with severe disease or complications such as bowel obstruction that does not respond to medication, surgical intervention may become necessary, though this is uncommon.^[11]

Monitoring and Follow-up

Because eosinophilic gastritis is a chronic condition that can flare up even after successful treatment, ongoing monitoring is essential. This typically involves periodic visits to a gastroenterologist, who will assess symptoms and may recommend repeat endoscopy with biopsies to check eosinophil levels in the stomach tissue. Blood tests may also be performed to monitor for complications such as anemia, nutritional deficiencies, or elevated eosinophil counts in the bloodstream. The frequency of follow-up depends on disease severity and how well symptoms are controlled, but most patients need at least annual evaluations, with more frequent monitoring during active treatment or when trying to identify food triggers.^[6][9]

Treatment in Clinical Trials

Because there are no medications specifically approved by the U.S. Food and Drug Administration for treating eosinophilic gastritis, researchers are actively studying new therapies through clinical trials. These studies aim to find treatments that are more effective, have fewer side effects, and can be used for long-term management of this chronic condition. Clinical trials represent an opportunity for patients to access cutting-edge therapies while contributing to scientific knowledge that may help others in the future.^[2][14]

Biological Therapies Targeting Immune Pathways

Much of the current research focuses on biological therapies—medications made from living cells that target specific parts of the immune system. Scientists have discovered that eosinophilic gastritis involves a particular type of immune response driven by substances called cytokines, especially those in the type 2 immune pathway. This includes molecules like interleukin-5 (IL-5), interleukin-4 (IL-4), and interleukin-13 (IL-13), which promote the growth, activation, and survival of eosinophils.^[5][15]

Anti-interleukin-5 therapies work by blocking IL-5, a key signal that tells the bone marrow to produce more eosinophils and tells existing eosinophils to survive longer and release their damaging contents. Several medications in this class are being studied for eosinophilic gastrointestinal disorders. These are given by injection under the skin or through an intravenous infusion at regular intervals. While these medications have shown promise in reducing eosinophil counts in the blood and tissues, researchers are still working to understand how well they control symptoms and whether they prevent long-term complications.^[15]

Another approach targets interleukin-4 and interleukin-13, which are involved in driving the allergic inflammation in the stomach. Medications that block the receptors for these cytokines prevent them from sending their inflammatory signals to cells. Some of these drugs are already approved for other allergic conditions, such as eczema and asthma, and are now being tested in eosinophilic gastrointestinal disorders. Early results have been encouraging, showing reductions in both eosinophil counts and symptoms in some patients.^[15]

Anti-IgE therapy is another biological approach. IgE is an antibody involved in allergic reactions, and blocking it may help reduce the allergic response driving eosinophil accumulation. This therapy has shown some benefit in small studies of eosinophilic gastrointestinal disorders.^[15]

Understanding Clinical Trial Phases

Clinical trials for new treatments progress through several phases, each designed to answer specific questions about safety and effectiveness. Phase I trials are the first studies in humans and focus primarily on safety. Researchers give the medication to a small group of volunteers—usually healthy people or, in some cases, patients with the disease—to learn about safe dosing, how the body processes the drug, and what side effects might occur.^[5]

Phase II trials examine whether the treatment actually works for the intended purpose. These studies enroll patients who have the disease and test whether the medication reduces eosinophil counts in tissue biopsies, improves symptoms, or achieves other markers of disease improvement. Phase II trials help researchers determine the best dose and identify which patients are most likely to benefit. These studies typically involve several dozen to a few hundred participants.^[5]

Phase III trials are large studies that compare the new treatment to current standard therapy or to a placebo—an inactive substance that looks like the medication but contains no active ingredient. These trials involve hundreds or even thousands of participants and are designed to provide definitive evidence about whether the new treatment is safe and effective enough to gain approval from regulatory agencies. If a medication successfully completes Phase III trials, the manufacturer can submit an application for approval to make the treatment available to all patients.^[5]

Phase IV trials occur after a medication has been approved and is available on the market. These studies continue to monitor long-term safety, identify rare side effects that might not have been detected in earlier trials, and explore whether the medication works in populations that were not included in the original studies.^[5]

Where Clinical Trials Are Happening

Research on eosinophilic gastritis and related conditions is being conducted at medical centers across the United States, Europe, and other regions. In the United States, a collaborative research network called the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR) brings together multiple academic medical centers to study these rare conditions. This consortium is funded by the National Institutes of Health and has established patient registries and research protocols specifically for eosinophilic gastrointestinal disorders.^[6][13]

Major children’s hospitals and academic medical centers with specialized programs in eosinophilic disorders often conduct clinical trials. Patients interested in participating can ask their gastroenterologist about available studies or search clinical trial registries online to find trials that match their situation. Eligibility criteria vary by study but typically include having a confirmed diagnosis of eosinophilic gastritis through endoscopy and biopsy, being within a certain age range, and not having other medical conditions that would interfere with the study.^[2][6]

Promising Results from Early Studies

While specific results from clinical trials of treatments for eosinophilic gastritis are still emerging, studies of biological therapies in related eosinophilic gastrointestinal disorders have shown encouraging signs. Some medications have demonstrated the ability to significantly reduce eosinophil counts in tissue biopsies, improve symptoms such as abdominal pain and nausea, and allow patients to expand their diets or reduce their reliance on corticosteroids. The safety profile of many of these biological therapies has been generally favorable, with side effects mostly limited to injection site reactions, headaches, or upper respiratory infections. However, longer-term studies are needed to fully understand the benefits and risks of these new treatments and to determine which patients are most likely to respond.^[15]

Most Common Treatment Methods

• Dietary modifications
  • Elemental diet using amino acid-based formulas that contain no intact proteins
  • Empiric elimination diet removing common food allergens such as milk, eggs, wheat, soy, nuts, and fish/seafood
  • Simplified one-food elimination diet, often starting with removal of animal milk products
  • Allergy testing-directed food elimination avoiding only foods that tested positive on skin or blood tests
  • Formula changes for infants, switching to hypoallergenic or amino acid-based options
• Corticosteroid therapy
  • Prednisone taken by mouth to reduce inflammation throughout the body
  • Budesonide formulations designed to work primarily in the digestive tract with fewer systemic effects
  • Initial high-dose treatment to achieve remission followed by gradual dose reduction
• Alternative medications
  • Mast cell stabilizers like cromolyn sodium to prevent release of inflammatory substances
  • Leukotriene inhibitors such as montelukast to block allergic reaction chemicals
  • Antihistamines to reduce effects of histamine release
  • Immunosuppressive agents like azathioprine for steroid-sparing therapy
• Biological therapies in clinical trials
  • Anti-interleukin-5 medications that block signals promoting eosinophil production and survival
  • Anti-interleukin-4 and anti-interleukin-13 therapies targeting allergic inflammation pathways
  • Anti-IgE therapy to reduce allergic antibody activity
• Supportive treatments
  • Iron supplements for patients with anemia from chronic stomach inflammation
  • Nutritional supplementation to address deficiencies from dietary restrictions
  • Regular monitoring through endoscopy with biopsies to assess treatment response
  • Blood tests to check eosinophil counts, anemia, and nutritional status